UBS Group AG Sells 51,622 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

UBS Group AG reduced its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 33.6% during the fourth quarter, HoldingsChannel reports. The firm owned 101,827 shares of the company’s stock after selling 51,622 shares during the period. UBS Group AG’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $2,426,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Russell Investments Group Ltd. boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock worth $146,000 after purchasing an additional 896 shares during the period. CIBC Private Wealth Group LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after purchasing an additional 1,103 shares during the last quarter. Cerity Partners LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 3.1% during the 2nd quarter. Cerity Partners LLC now owns 41,126 shares of the company’s stock valued at $1,175,000 after purchasing an additional 1,223 shares during the period. Sei Investments Co. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 10.2% during the 3rd quarter. Sei Investments Co. now owns 13,879 shares of the company’s stock valued at $365,000 after purchasing an additional 1,287 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Fresenius Medical Care AG & Co. KGaA by 13.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 11,533 shares of the company’s stock valued at $304,000 after purchasing an additional 1,372 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS opened at $21.59 on Wednesday. The company has a 50-day simple moving average of $22.37 and a two-hundred day simple moving average of $23.01. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86. The firm has a market capitalization of $12.06 billion, a PE ratio of 11.36, a price-to-earnings-growth ratio of 3.90 and a beta of 0.81. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.02 and a one year high of $29.71.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The firm had revenue of $5.34 billion for the quarter. On average, analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The company also recently declared an annual dividend, which will be paid on Monday, June 8th. Investors of record on Friday, May 22nd will be paid a $0.8716 dividend. The ex-dividend date of this dividend is Friday, May 22nd. This is a positive change from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. This represents a yield of 402.0%. Fresenius Medical Care AG & Co. KGaA’s payout ratio is currently 32.11%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, April 24th. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Finally, Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Five research analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Reduce” and a consensus target price of $28.00.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.